MedTrace Logo

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00735917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-04-02

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Adenocarcinoma of the Pancreas
  • Recurrent Pancreatic Cancer
  • Stage IV Pancreatic Cancer

Interventions

DRUG

saracatinib

Given PO

OTHER

pharmacogenomic studies

Optional correlative studies

OTHER

pharmacological study

Optional correlative studies

PROCEDURE

positron emission tomography

Optional correlative studies

RADIATION

fludeoxyglucose F 18

Optional correlative studies

OTHER

laboratory biomarker analysis

Optional correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Wells Messersmith · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-04-30
Completion
2012-10-31

Countries

  • United States
  • Australia
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00735917 on ClinicalTrials.gov